...
首页> 外文期刊>Southern African Journal of Epidemiology and Infection >The effect of prior antimicrobial therapy for community acquired infections on the aetiology of early and late onset ventilator-associated pneumonia in a level I trauma intensive care unit
【24h】

The effect of prior antimicrobial therapy for community acquired infections on the aetiology of early and late onset ventilator-associated pneumonia in a level I trauma intensive care unit

机译:在I级创伤重症监护病房中,先前针对社区获得性感染的抗微生物药物治疗对早期和晚期呼吸机相关性肺炎的病因学的影响

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Ventilator-associated pneumonia (VAP) is the most common hospital acquired infection in patients who require mechanical ventilation. Early VAP is associated with community acquired pathogens whereas late VAP involves hospital flora. Based on this premise, a protocol may be formulated for microbiological surveillance and antimicrobial stewardship within a specific intensive care unit (ICU) to ensure appropriate empiric antimicrobial choice. The bacterial flora in VAP may be affected, however, by antimicrobials prescribed during the ICU stay. Aim: The aim of this study was to determine the effect of prior antimicrobial therapy for community acquired infections on aetiology and the susceptibility of bacterial isolates from the first episode of early or late VAP in a trauma intensive care unit. Methods: Endotracheal aspirates (ETAs) were obtained from patients with suspected early and late VAP. All ETAs were processed and interpreted as per the Clinical and Laboratory Standards Institute (CLSI). Patients were divided into two cohorts: those whose injuries had required antimicrobial therapy for community acquired infections and those who were antimicrobial na?ve. The effect of prior antimicrobial therapy on bacterial isolates from the first episode of suspected VAP was compared between the two groups. Results: Of 288 patients admitted to the Trauma ICU between January and December 2014, pneumonia was suspected in 91 (31.6%). Of these, 69 (76%) patients were antimicrobial na?ve and 22 (24%) had received prior antimicrobial therapy. Early VAP occurred in 31 (45%) patients in the na?ve cohort compared to 3 (12.5%) with prior antimicrobial exposure ( p = 0.01). Of the early VAP isolates 25 (81%) in the na?ve cohort contained community flora, whereas all isolates in those with prior antimicrobial therapy revealed hospital acquired organisms ( p = 0.01). In the antimicrobial na?ve cohort with late VAP 27 (71%) patients had community acquired organisms, whereas only 3 (16%) isolates in late VAP in those with prior therapy revealed community acquired flora ( p Conclusion: Patients who receive prior antimicrobial therapy have a significantly lower incidence of early VAP, but in those who developed either early or late VAP hospital acquired pathogens were more commonly isolated. Knowledge of prior antimicrobial exposure in a patient with early or late VAP will assist in determining the correct empiric antimicrobial choice. (Full text available online at www.medpharm.tandfonline.com/ojid ) South Afr J Infect Dis 2017; DOI: 10.1080/23120053.2017.1313933
机译:背景:呼吸机相关性肺炎(VAP)是需要机械通气的患者中最常见的医院获得性感染。早期VAP与社区获得性病原体相关,而晚期VAP涉及医院菌群。基于此前提,可以制定一个协议,以在特定的重症监护病房(ICU)中进行微生物监测和抗菌管理,以确保选择适当的经验性抗菌药物。 VAP中的细菌菌群可能会受到ICU停留期间处方的抗菌药物的影响。目的:本研究的目的是确定在创伤重症监护室中,针对社区获得性感染的先前抗微生物治疗对病因学和早期或晚期VAP首次发作的细菌分离物的敏感性。方法:从疑似早期和晚期VAP患者中获取气管内抽吸物(ETA)。所有ETA均根据临床和实验室标准协会(CLSI)进行处理和解释。将患者分为两个队列:受伤者需要对社区获得性感染进行抗菌治疗,以及初次接受抗菌治疗的患者。在两组之间比较了先前的抗菌治疗对疑似VAP首次发作的细菌分离物的影响。结果:2014年1月至2014年12月,在288例创伤性ICU住院患者中,有91例(31.6%)被怀疑患有肺炎。在这些患者中,有69名(76%)的患者是初次使用过抗菌药物的患者,有22名(24%)曾接受过抗菌药物的治疗。初次队列中有31例患者(45%)发生了早期VAP,而之前曾接受过抗生素暴露的患者中有3例(12.5%)(P = 0.01)。在初次队列中,早期VAP分离株中有25个(81%)含有群落菌群,而先前进行过抗微生物治疗的患者中的所有分离株均显示出医院获得的细菌(p = 0.01)。在晚期VAP的初治抗菌药物队列中,有27例(71%)患者具有社区获得性微生物,而先前接受过治疗的患者中只有3例(16%)晚期VAP分离株显示出社区获得性菌群(p结论:先前接受过抗菌药物的患者早期VAP的发生率显着降低,但是在那些发生早期或晚期VAP的患者中,病原菌的分离更为普遍,了解早期或晚期VAP患者的先前抗菌药物暴露将有助于确定正确的经验性抗菌药物选择。(全文可在线访问www.medpharm.tandfonline.com/ojid)South Afr J Infect Dis 2017; DOI:10.1080 / 23120053.2017.1313933

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号